InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) Backed by Seasoned Management

CFN Media Group, the pioneering creative agency and digital media network committed to legal cannabis reported the publication of a video and article of CEO interview talking on InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) uniquely efficient approach to the growing cannabis biopharmaceutical industry.

The highlights

The pharmaceutical industry shows the sole largest subset of the cannabis market, as per Bloomberg’s 2015 Weed Index. This industry had a combined market cap of more than $1.5 billion. Since then, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)‘s market cap alone has soared to almost $3 billion and enhanced the value of the pharmaceutical aspect of the operations well beyond producers, consulting, dispensaries, real estate and other industry subsets.

The most vital indicator of success for numerous micro-cap firms is their management team since there is often no existing profit or revenue. InMed’s management has combined experience in business development, marketing and sales, capital formation, drug development and regulatory affairs. Dr. Ado Muhammad became the firm’s Chief Medical Officer after working as the Associate Medical Director for GW, specializing in the advancement of cannabinoid-based prescription drugs.

He is the only ex Senior GW team member currently involved with a Hemp biopharmaceutical firm in all of North America.

InMed Pharmaceuticals has advanced an approach that reduces the time, cost and associated risks to getting cannabinoids to market. Utilizing a patented bioinformatics analysis tool, the firm can rapidly identify specific cannabinoids, of more than 90 in the cannabis crop, that could play a vital role in treating certain diseases by analyzing the structures of researched and approved medications, genetic profiles of diseases, and several other factors.

It helps lessen the time to market and enhance the likelihood of success. InMed has advanced its two lead compounds via this system, INM-085 for Glaucoma and INM-750 for Epidermolysis Bullosa. Also, utilizing natural compounds with understood safety profiles adds significantly to minimize risk of clinical failure because of safety issues.